X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AJANTA PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AJANTA PHARMA PFIZER/
AJANTA PHARMA
 
P/E (TTM) x 31.1 24.5 127.0% View Chart
P/BV x 5.0 10.1 49.0% View Chart
Dividend Yield % 0.7 0.6 110.2%  

Financials

 PFIZER   AJANTA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
AJANTA PHARMA
Mar-16
PFIZER/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7241,720 158.4%   
Low Rs1,6111,103 146.1%   
Sales per share (Unadj.) Rs440.9194.6 226.5%  
Earnings per share (Unadj.) Rs48.745.2 107.7%  
Cash flow per share (Unadj.) Rs75.850.3 150.7%  
Dividends per share (Unadj.) Rs15.008.00 187.5%  
Dividend yield (eoy) %0.70.6 122.1%  
Book value per share (Unadj.) Rs462.9132.0 350.6%  
Shares outstanding (eoy) m45.7588.77 51.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.97.3 67.8%   
Avg P/E ratio x44.531.2 142.6%  
P/CF ratio (eoy) x28.628.1 101.9%  
Price / Book Value ratio x4.710.7 43.8%  
Dividend payout %30.817.7 174.1%   
Avg Mkt Cap Rs m99,163125,299 79.1%   
No. of employees `0002.9NA-   
Total wages/salary Rs m2,7582,570 107.3%   
Avg. sales/employee Rs Th6,981.7NM-  
Avg. wages/employee Rs Th954.5NM-  
Avg. net profit/employee Rs Th771.1NM-  
INCOME DATA
Net Sales Rs m20,17017,275 116.8%  
Other income Rs m857166 515.6%   
Total revenues Rs m21,02817,442 120.6%   
Gross profit Rs m4,3105,807 74.2%  
Depreciation Rs m1,239451 274.9%   
Interest Rs m549 10.6%   
Profit before tax Rs m3,9235,474 71.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7941,460 122.9%   
Profit after tax Rs m2,2284,014 55.5%  
Gross profit margin %21.433.6 63.6%  
Effective tax rate %45.726.7 171.5%   
Net profit margin %11.023.2 47.5%  
BALANCE SHEET DATA
Current assets Rs m16,2997,639 213.4%   
Current liabilities Rs m7,5942,715 279.7%   
Net working cap to sales %43.228.5 151.4%  
Current ratio x2.12.8 76.3%  
Inventory Days Days6543 151.0%  
Debtors Days Days2679 32.7%  
Net fixed assets Rs m8,6226,914 124.7%   
Share capital Rs m458177 258.6%   
"Free" reserves Rs m20,72211,442 181.1%   
Net worth Rs m21,18011,721 180.7%   
Long term debt Rs m25149 16.8%   
Total assets Rs m29,13714,814 196.7%  
Interest coverage x755.5112.9 668.9%   
Debt to equity ratio x00 9.3%  
Sales to assets ratio x0.71.2 59.4%   
Return on assets %7.727.4 27.9%  
Return on equity %10.534.2 30.7%  
Return on capital %19.046.5 40.8%  
Exports to sales %0.155.1 0.1%   
Imports to sales %17.56.0 291.0%   
Exports (fob) Rs m129,527 0.1%   
Imports (cif) Rs m3,5261,038 339.8%   
Fx inflow Rs m5210,422 0.5%   
Fx outflow Rs m1401,678 8.3%   
Net fx Rs m-888,744 -1.0%   
CASH FLOW
From Operations Rs m3,4363,264 105.3%  
From Investments Rs m-6,991-2,093 334.0%  
From Financial Activity Rs m-619-1,186 52.2%  
Net Cashflow Rs m-4,174-15 28,199.3%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 1.6 483.9%  
FIIs % 4.9 7.6 64.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.0 139.4%  
Shareholders   85,207 20,968 406.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ASTRAZENECA PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK PFIZER

PFIZER - ALEMBIC PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS